Allogene Therapeutics, Inc. (ALLO) › Shareholders' EquityAllogene Therapeutics, Inc. (ALLO) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2017: -$2.0K2018: $703.16M2019: $629.02M2020: $1.01B2021: $925.20M2022: $666.88M2023: $512.23M2024: $422.18M2025: $292.54M$292.54M2017Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$292.54M-30.7%2024$422.18M-17.6%2023$512.23M-23.2%2022$666.88M-27.9%2021$925.20M-8.7%2020$1.01B+61.1%2019$629.02M-10.5%2018$703.16M+35158300.0%2017-$2.0K—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share